Canaccord Genuity Reiterates a 'Buy' on InterMune Inc. (ITMN); Esbriet (pirfenidone) Positive GBA Assessment
Tweet
Share
E-mailGet Alerts ITMN Hot Sheet
Price: $73.89 --0%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 31
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 31
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on InterMune Inc. (NASDAQ: ITMN) price target of $24.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Esbriet (pirfenidone) positive GBA assessment, potential for blockbuster worldwide sales, US clinical success. Esbriet is ITMN’s drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We see major Esbriet EU commercial potential (despite price concerns), encouraging 2012 adoption, and worldwide peak sales of ~$4B."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $10.08 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Esbriet (pirfenidone) positive GBA assessment, potential for blockbuster worldwide sales, US clinical success. Esbriet is ITMN’s drug for idiopathic pulmonary fibrosis (IPF), an orphan lung disease. We see major Esbriet EU commercial potential (despite price concerns), encouraging 2012 adoption, and worldwide peak sales of ~$4B."
For an analyst ratings summary and ratings history on InterMune Inc. click here. For more ratings news on InterMune Inc. click here.
Shares of InterMune Inc. closed at $10.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
- Braze Inc (BRZE) PT Raised to $40 at DA Davidson
- Palo Alto Networks (PANW) PT Raised to $420 at DA Davidson on Strong Q4 Upside
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
